GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » EBITDA Margin %

NextCure (FRA:2US) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is NextCure EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. NextCure's EBITDA for the three months ended in Dec. 2024 was €-11.25 Mil. NextCure's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, NextCure's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


NextCure EBITDA Margin % Historical Data

The historical data trend for NextCure's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure EBITDA Margin % Chart

NextCure Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial -168.96 - - - -

NextCure Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NextCure's EBITDA Margin %

For the Biotechnology subindustry, NextCure's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCure's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where NextCure's EBITDA Margin % falls into.


;
;

NextCure EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

NextCure's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-51.896/0
= %

NextCure's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-11.251/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCure  (FRA:2US) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


NextCure EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of NextCure's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NextCure Business Description

Traded in Other Exchanges
Address
9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

NextCure Headlines

No Headlines